Search clinical trials for: Exenatide extended release 2mg (Bydureon)

Total 1044 results

University College, London

Active, not recruiting

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease (Exenatide-PD3)

Parkinson's Disease

United Kingdom
Chinese University of Hong Kong

Recruiting

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (GAPP-SVD)

Cerebral Small Vessel Disease

Hong Kong
Vivani Medical, Inc
Medpace, Inc.

Not yet recruiting

Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes (LIBERATE-1)

Type 2 Diabetes
Vanderbilt University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

Diabetes Mellitus | Human Immunodeficiency Virus Infection

United States
University at Buffalo
AstraZeneca

Completed

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

Evaluate Ketogenic Stress

United States
University at Buffalo
AstraZeneca

Terminated

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes (1981)

Kidney Diseases | Type2 Diabetes

United States
Anders Fink-Jensen, MD, DMSci
The Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaborators

Completed

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? (EXALT)

Addiction, Alcohol | Alcohol Dependence, in Remission

Denmark
AstraZeneca

Completed

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Type 2 Diabetes Mellitus

Canada, United States
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
The University of Texas Health Science Center,...
The Center for Clinical and Translational Sciences (CCTS) Clinical Research...

Completed

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Obesity | Prediabetes

United States
The University of Texas Health Science Center,...

Completed

Exenatide for Treating Cocaine Use Disorder

Cocaine Use Disorder

United States
University of Palermo
AstraZeneca

Completed

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

Type 2 Diabetes Mellitus

Italy
Consano Clinical Research, LLC

Completed

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Diabetes Mellitus, Type 2

United States
OPKO Health, Inc.

Completed

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Romania, Poland, Mexico, Greece
AstraZeneca
Eli Lilly and Company

Completed

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
AstraZeneca

Completed

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. (Bydureon)

Type 2 Diabetes Mellitus

Korea, Republic of
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
AstraZeneca

Completed

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Type 2 Diabetes

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Ingrid Jazet
AstraZeneca

Unknown

Exenatide and Brown Adipose Tissue (exe01)

Obesity

Netherlands
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States
University College, London

Unknown

Exenatide Once-weekly as a Treatment for Multiple System Atrophy (MSA)

Multiple System Atrophy

United Kingdom
Seattle Children's Hospital
University of Washington

Recruiting

Brain Activation and Satiety in Children 2 (BASIC2)

Childhood Obesity

United States
AstraZeneca
Eli Lilly and Company

Completed

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Yale University

Completed

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Type I Diabetes

United States
University of Minnesota

Completed

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

Severe Obesity

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Erasme University Hospital

Terminated

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Type 2 Diabetes | Pancreas | Incretinomimetics

Belgium
AstraZeneca

Completed

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Children and Adolescent With Type 2 Diabetes

United States, Hungary, Israel, Mexico, Bulgaria, Ukraine, Kuwait
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Puerto Rico, United Kingdom, Argentina, Finland, Serbia, Germany, France, Greece, Netherlands, Switzerland
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)

Alzheimer's Disease

United States, Germany, France, Poland, Portugal, Spain, Canada, Argentina, Chile, India, Greece, Hungary, Italy, Japan, Austria, Brazil, Czechia, Mexico, Switzerland
Phoenix VA Health Care System

Unknown

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
University of Guadalajara

Unknown

Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

Diabetes Mellitus, Type 2

Mexico
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Xiangya Hospital of Central South University

Recruiting

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Obesity

China
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (LixiLan-G)

Type 2 Diabetes Mellitus

Estonia, Italy, Israel, United States, Canada, Germany, Romania, Slovakia, Spain
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Alvogen Korea

Completed

Phase IV Study of Qsymia in Obese Patients

Obesity

Korea, Republic of
Peking Union Medical College Hospital

Unknown

Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

Polycystic Ovary Syndrome

China

3

Subscribe